Priya Singhal
Insider (Form 4 reporting owner): Head of Development CIK 1769608Name as filed: Singhal PriyaIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 28 Mar 2023, sold $2.0M in 16 sales (15 under a 10b5-1 plan set in advance) of Biogen.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Biogen BIIB | Head of Development | 28 Mar 2023 | 9 Feb 2026 | – | 16$2.0M |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After sales | -3.1 pts12 trades, 42% above the sector | -12.1 pts12 trades, 25% above the sector | -34.9 pts11 trades, 27% above the sector |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 2 | $666K | -$666K |
| 2025 | – | – | 2 | $550K | -$550K |
| 2024 | – | – | 7 | $463K | -$463K |
| 2023 | – | – | 5 | $345K | -$345K |
Every trade
16, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 9 Feb 2026 | Biogen BIIB | Sellafter exercising options | 2,660 | $199.83 | $532K | 10b5-1 plan | Form 4filed 10 Feb 2026 |
| 2 Feb 2026 | Biogen BIIB | Sellafter exercising options | 748 | $179.30 | $134K | 10b5-1 plan | Form 4filed 3 Feb 2026 |
| 2 Sep 2025 | Biogen BIIB | Sellafter exercising options | 517 | $133.55 | $69K | 10b5-1 plan | Form 4filed 2 Sep 2025 |
| 19 May 2025 | Biogen BIIB | Sell | 3,806 | $126.25 | $481K | 10b5-1 plan | Form 4filed 20 May 2025 |
| 9 Dec 2024 | Biogen BIIB | Sellafter exercising options | 110 | $157.21 | $17K | 10b5-1 plan | Form 4filed 9 Dec 2024 |
| 3 Sep 2024 | Biogen BIIB | Sellafter exercising options | 431 | $204.22 | $88K | 10b5-1 plan | Form 4filed 5 Sep 2024 |
| 2 Apr 2024 | Biogen BIIB | Sell | 93 | $213.09 | $20K | 10b5-1 plan | Form 4filed 3 Apr 2024 |
| 22 Feb 2024 | Biogen BIIB | Sell | 262 | $221.23 | $58K | 10b5-1 plan | Form 4filed 26 Feb 2024 |
| 16 Feb 2024 | Biogen BIIB | Sellafter exercising options | 108 | $221.49 | $24K | 10b5-1 plan | Form 4filed 21 Feb 2024 |
| 12 Feb 2024 | Biogen BIIB | Sellafter exercising options | 419 | $239.45 | $100K | 10b5-1 plan | Form 4filed 13 Feb 2024 |
| 2 Feb 2024 | Biogen BIIB | Sellafter exercising options | 634 | $245.93 | $156K | 10b5-1 plan | Form 4filed 5 Feb 2024 |
| 11 Dec 2023 | Biogen BIIB | Sellafter exercising options | 110 | $248.00 | $27K | 10b5-1 plan | Form 4filed 12 Dec 2023 |
| 5 Sep 2023 | Biogen BIIB | Sellafter exercising options | 431 | $269.43 | $116K | 10b5-1 plan | Form 4filed 6 Sep 2023 |
| 3 Jul 2023 | Biogen BIIB | Sellafter exercising options | 81 | $282.87 | $23K | 10b5-1 plan | Form 4filed 5 Jul 2023 |
| 4 Apr 2023 | Biogen BIIB | Sell | 91 | $277.11 | $25K | 10b5-1 plan | Form 4filed 6 Apr 2023 |
| 28 Mar 2023 | Biogen BIIB | Sell | 568 | $270.06 | $153K | No | Form 4filed 30 Mar 2023 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.